This segment focuses on the research, development, and commercialization of innovative treatments for central nervous system disorders. Aquestive Therapeutics utilizes its proprietary PharmFilm® technology to create oral soluble film formulations for improved drug delivery and patient outcomes. Key products include Sympazan® (clobazam) for Lennox-Gastaut syndrome and Libervant® (diazepam) for seizures. Research and development efforts are centered on expanding the CNS pipeline with novel formulations and indications. The company is actively involved in clinical trials to evaluate the efficacy and safety of its products. Market positioning emphasizes the advantages of oral soluble film technology, such as ease of administration and improved bioavailability, offering a competitive edge in the treatment of neurological conditions. Future opportunities include expanding the product portfolio and exploring partnerships to broaden market reach. Regulatory aspects involve obtaining FDA approvals and adhering to stringent quality standards. This segment aims to improve the lives of patients suffering from debilitating neurological conditions by providing effective and convenient treatment options.

This segment is dedicated to the development and commercialization of treatments for opioid dependence. Aquestive Therapeutics markets Suboxone®, a sublingual film formulation of buprenorphine and naloxone. The company's research and development efforts focus on optimizing the formulation and delivery of buprenorphine and naloxone to improve patient adherence and outcomes. The technology used is the PharmFilm® platform, which allows for rapid absorption and ease of use. The patient impact is significant, as Suboxone® helps individuals overcome opioid addiction and regain control of their lives. Market positioning is strong due to the effectiveness and convenience of the sublingual film. Future opportunities include exploring new formulations and expanding the product line. Regulatory aspects involve FDA approval and adherence to strict guidelines for controlled substances. Partnerships with healthcare providers and addiction treatment centers are crucial for market access and patient support. The segment aims to provide accessible and effective treatment options to combat the opioid crisis.

This segment focuses on developing and commercializing life-saving treatments for emergency medical conditions, particularly allergic reactions and anaphylaxis. Aquestive Therapeutics is developing AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. The company's research and development efforts are focused on creating a convenient and effective epinephrine delivery system. The technology used is the PharmFilm® platform, which allows for rapid absorption and ease of use. The patient impact is significant, as AQST-109 has the potential to save lives by providing a readily available treatment for anaphylaxis. Market positioning is strong due to the unmet need for a convenient and reliable epinephrine delivery system. Future opportunities include expanding the product line and exploring partnerships to broaden market reach. Regulatory aspects involve FDA approval and adherence to strict guidelines for emergency medications. This segment aims to provide accessible and effective treatment options to combat life-threatening allergic reactions.